Press Release

Hyper-Transmissible SARS-CoV-2 Variant Detected in U.S. Wastewater

Date of Release: Jan. 15, 2021

FORT COLLINS, Colo, /PRNewswire/ — GT Molecular, a leader in wastewater-based epidemiological testing, has reported the detection of hyper-transmissible SARS-CoV-2 from the B.1.1.7 lineage in three wastewater treatment plants in the United States. This is an additional piece of evidence that the UK variant or a UK variant-like strain is spreading in the United States. GT Molecular detected the strain using its highly sensitive digital PCR test for the SARS-CoV-2 virus. This test is available immediately both as a fee-for-service and as a complete, ready-to-use PCR kit for testing labs.

“Molecular biologists from around the world have come together to advance wastewater-based epidemiological approaches over the last year. This is an excellent demonstration of the power of these approaches, wherein an entire community can be tested for the presence of a variant in a single sample in a matter of hours,” says, Dr. Rose Nash, Director of R&D at GT Molecular.

GT Molecular will continue to screen communities around the country for the presence of this variant in their community wastewater through their nationwide wastewater testing program. Additionally, GT Molecular will provide the molecular reagents they designed and optimized for this analysis to the greater wastewater-based epidemiology community.

“Our team continues to respond rapidly to this pandemic by releasing both a fee-for-service test for communities and an all-in-one PCR kit for testing labs for this dangerous variant,” says GT Molecular CEO Christopher McKee. “Our new analysis will allow communities and testing labs to quickly determine whether the SARS-CoV-2 B.1.1.7 variant is present while giving health officials timely data to make decisions that can better help manage outbreaks.”

About GT Molecular

Whether for cancer, GMO or harmful pathogens, GT Molecular (GTM) is a leader in providing highly customizable, ultrasensitive digital PCR and qPCR tests for researchers and the Molecular Diagnostics community. GTM’s molecular app technology is an easy-to-use, end-to-end solution for rapid deployment and provides reliable and consistent measurements while detecting as little as 1-3 molecules of target nucleic acid.

The SARS-CoV-2 B1.1.7 (UK Variant) test is available immediately both as a fee-for-service and as a complete, ready-to-use PCR kit for testing labs.

ORDER & INFORMATION: info@gtmolecular.com 
970-498-1698

www.gtmolecular.com

SOURCE GT Molecular

Medika Life

Medika Life is a digital Health Publication for both the medical profession and the public. Make informed decisions about your health and stay up to date with the latest developments and technological advances in the fields of medicine.

Recent Posts

Ukraine: Worn Hearts, Steeled Resolve

I have traveled to Ukraine nearly 20 times. Each visit deepens my respect for how…

1 week ago

Medicaid at a Crossroads: Safe AI, Shifting Policy and the Stakes for People’s Health

Medicaid is one of America’s most complex and essential Federal health programs, serving more than…

3 weeks ago

Global childhood vaccination remains resilient, but equity cracks are widening

In 2024, immunisation data from WHO and UNICEF show that while 115 million infants (89%) received at…

3 weeks ago

Restrictive practices in medicine are holding high-income countries back

A paper in this week’s New England Journal of Medicine (NEJM) is part of a…

3 weeks ago

The Trauma of Witnessing Charlie Kirk’s Murder and PTSD

The psychological effects of public space shootings extend beyond physical harm because they create a…

3 weeks ago

Guns, Race, and Profit: The Pain of America’s Other Epidemic

BOGALUSA, La. — Less than a mile from a century-old mill that sustained generations in…

1 month ago

This website uses cookies. Your continued use of the site is subject to the acceptance of these cookies. Please refer to our Privacy Policy for more information.

Read More